<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inhalation anesthetic agents: Clinical effects and uses</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inhalation anesthetic agents: Clinical effects and uses</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inhalation anesthetic agents: Clinical effects and uses</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Robert Hays, MD, FAAP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1637840784"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will review the anesthetic and other clinical effects of inhalation anesthetics including the potent volatile agents (<a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> [and in some countries, halothane]) and one gas (<a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> [N<sub>2</sub>O]), as well as their use to induce and maintain general anesthesia. Properties of the inhalation anesthetics and techniques for their delivery via an anesthesia machine are discussed separately. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery"</a> and  <a class="medical medical_review" href="/d/html/94594.html" rel="external">"Anesthesia machines: Prevention, diagnosis, and management of malfunctions"</a>.)</p><p>Clinical uses of intravenous agents to induce and maintain general anesthesia are reviewed in separate topics. (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents"</a> and  <a class="medical medical_review" href="/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Total intravenous anesthesia'</a>.)</p><p class="headingAnchor" id="H2396769484"><span class="h1">CLINICAL EFFECTS</span><span class="headingEndMark"> — </span>Inhalation anesthetics produce sedation on a spectrum up to and including general anesthesia as well as other clinical effects. Pharmacodynamic parameters for each agent describe these effects (ie, what the drug does to the body).</p><p class="headingAnchor" id="H1528378748"><span class="h2">Sedation and anesthesia</span></p><p class="headingAnchor" id="H4120616033"><span class="h3">Continuum of effect: sedation to general anesthesia</span><span class="headingEndMark"> — </span>Inhalation anesthetic agents demonstrate a dose-response effect, with progressively higher doses providing progressively deeper levels of sedation and anesthesia. General anesthesia is a reversible state that includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypnosis (ie, loss of consciousness)</p><p class="bulletIndent1"><span class="glyph">●</span>Amnesia (ie, lack of recall)</p><p class="bulletIndent1"><span class="glyph">●</span>Analgesia (ie, pain relief)</p><p class="bulletIndent1"><span class="glyph">●</span>Akinesia (ie, immobility)</p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic and somatic block</p><p></p><p>Inhalation agents are complete general anesthetic agents, in that they provide all of these components at clinically relevant concentrations.</p><p class="headingAnchor" id="H2769569626"><span class="h3">MAC and MAC-awake values for inhalation agents</span><span class="headingEndMark"> — </span>The minimum alveolar concentration (MAC) and MAC-awake values are measures of inhalation anesthetic potency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MAC value</strong> – The MAC value is the concentration of an inhalation agent in the alveoli required to prevent movement in response to a noxious stimulus in 50 percent of subjects after allowing sufficient time for uptake and redistribution of the inhalation agent to reach a steady state  (<a class="graphic graphic_table graphicRef109424" href="/d/graphic/109424.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. In human studies, the tested noxious stimulus is typically a skin incision. Thus, MAC is the effective dose (ED)<sub>50</sub> for absence of movement in response to surgical pain.</p><p></p><p class="bulletIndent1">MAC values differ for each inhalation anesthetic agent  (<a class="graphic graphic_table graphicRef109494" href="/d/graphic/109494.html" rel="external">table 2</a>). Only <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> (N<sub>2</sub>O) gas has a MAC value &gt;100 (105 percent at standard pressure and temperature). Thus, N<sub>2</sub>O has extremely low potency, and MAC cannot be achieved when N<sub>2</sub>O is delivered under standard conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MAC-awake value</strong> – The MAC-awake (also termed MAC-aware) value is the concentration of an inhalation agent in the alveoli at which 50 percent of patients will not respond to a verbal or non-noxious tactile stimulus. Thus, MAC-awake is the ED<sub>50</sub> for response to voice or light touch and is thought to approximate the ED<sub>50</sub> required for perceptive awareness and anesthetic recall. For each inhalation agent, MAC-awake values are approximately 40 percent of the standard MAC value required to tolerate surgical stimuli without movement.</p><p></p><p class="headingAnchor" id="H3892670999"><span class="h3">Influence of drug-drug interactions</span><span class="headingEndMark"> — </span>The anesthetic effects of the different inhalation agents are additive. For example, if N<sub>2</sub>O is administered at 0.5 MAC (approximately 50 percent N<sub>2</sub>O concentration) together with <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> administered at 0.5 MAC (approximately 0.6 percent isoflurane concentration), then the additive anesthetic effects should be approximately 1.0 MAC.</p><p>MAC for any inhalation anesthetic is decreased by concurrent administration of any intravenous (IV) anesthetic, sedative, and/or analgesic agent (eg, sedative-hypnotics, benzodiazepines, opioids, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>) [<a href="#rid2">2</a>].</p><p>When anesthetic drugs from different classes are combined, the effects are typically synergistic rather than merely additive [<a href="#rid3">3</a>]. Synergy is particularly common when drugs acting primarily on gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptors (eg, volatile inhalation agents, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, benzodiazepines) are combined with drugs acting on other receptor types (eg, opioids).</p><p>MAC is decreased by acute alcohol use due to its sedative effects, or chronic use of amphetamines or alpha2 agonists, which may deplete central nervous system (CNS) catecholamine levels  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 3</a>). Conversely, MAC is increased by chronic alcohol use (likely due to enhanced hepatic metabolism) and by recent use of either amphetamines, cocaine, or <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a> since these agents may acutely increase CNS catecholamine levels that enhance focused consciousness  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H2587108057"><span class="h3">Influence of patient-related factors</span><span class="headingEndMark"> — </span>MAC values are also influenced by patient age and coexisting conditions  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 3</a>) [<a href="#rid4">4</a>]. Awareness of such effects is important to avoid inadequate anesthesia or, conversely, anesthetic overdose.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age </strong>– In general, MAC decreases incrementally with age, as shown in figures for <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>  (<a class="graphic graphic_figure graphicRef113991" href="/d/graphic/113991.html" rel="external">figure 1</a>), <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>  (<a class="graphic graphic_figure graphicRef117701" href="/d/graphic/117701.html" rel="external">figure 2</a>), and <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>  (<a class="graphic graphic_figure graphicRef117702" href="/d/graphic/117702.html" rel="external">figure 3</a>). MAC is reduced at the extremes of age (eg, premature infants or patients &gt;60 years old), although effects vary by agent. For more soluble agents such as halothane  (<a class="graphic graphic_figure graphicRef117700" href="/d/graphic/117700.html" rel="external">figure 4</a>) and isoflurane  (<a class="graphic graphic_figure graphicRef113990" href="/d/graphic/113990.html" rel="external">figure 5</a>), MAC is reduced at birth, particularly in premature infants, rising until around age six months before beginning to decrease with further aging. For newer less soluble agents such as sevoflurane  (<a class="graphic graphic_figure graphicRef117577" href="/d/graphic/117577.html" rel="external">figure 6</a>) and desflurane  (<a class="graphic graphic_figure graphicRef117700" href="/d/graphic/117700.html" rel="external">figure 4</a>), and for N<sub>2</sub>O  (<a class="graphic graphic_figure graphicRef117700" href="/d/graphic/117700.html" rel="external">figure 4</a>), decreases in MAC have not been demonstrated in young infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors </strong>– Typically, MAC is markedly reduced in patients with certain acute conditions including severe anemia with hemoglobin &lt;5 g/dL, hypothermia, hypercarbia, hypoxia, metabolic acidosis, shock, or acute electrolyte abnormalities  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1">Also, pregnancy decreases MAC, as does clinical hypothyroidism. In one study, the MAC-awake value for <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> in patients with end-stage renal disease (ESRD) was lower than that in patients without renal disease (0.59 percent, 95% CI 0.50-0.66 percent versus 0.71 percent, 95% CI 0.63-0.80 percent) [<a href="#rid5">5</a>]. This may be due to altered brain sensitivity to anesthetic agents in ESRD.</p><p></p><p class="bulletIndent1">Conversely, hyperthermia, hyperthyroidism, anxiety, and other conditions associated with psychomotor activation increase MAC  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 3</a>).</p><p></p><p class="headingAnchor" id="H28314396"><span class="h3">Monitoring anesthetic effect</span><span class="headingEndMark"> — </span>Continuous monitoring of the end-tidal anesthetic concentration (ETAC) of the inhaled anesthetic agent is typically used to titrate the inhalation anesthetic. An ETAC concentration close to the MAC value for the selected inhalation agent is typically targeted, in order to maintain adequate anesthetic depth and avoid intraoperative awareness. In addition, raw or processed electroencephalography or other neuromonitoring techniques may be employed to aid in managing dosing in older adults and other patients at risk for excessive anesthetic depth, thereby avoiding doses that are either excessive or inadequate for an individual patient  (<a class="graphic graphic_table graphicRef81084" href="/d/graphic/81084.html" rel="external">table 4</a>) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/d/html/14931.html" rel="external">"Anesthesia for the older adult", section on 'Anesthetic depth: General considerations'</a>.)</p><p class="headingAnchor" id="H425000324"><span class="h2">Other clinical effects</span></p><p class="headingAnchor" id="H443815897"><span class="h3">Skeletal and smooth muscle relaxation</span><span class="headingEndMark"> — </span>All potent volatile inhalation anesthetics induce dose-dependent relaxation of both skeletal and smooth muscle by inhibiting nicotinic acetylcholine receptors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skeletal muscle relaxation </strong>– The volatile inhalation agents potentiate and reduce the required dose of a neuromuscular blocking agent (NMBA). The degree of potentiation of NMBA effect depends upon the concentration of inhalation anesthetic administered, the duration of exposure, and the specific agent. The degree to which each inhalation agent potentiates NMBA effects (from highest to lowest) is (see  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Drug interactions'</a>):</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> &gt; <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> &gt; <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> &gt; halothane &gt; N<sub>2</sub>O </p></div></div><p></p><p class="bulletIndent1">The degree of skeletal muscle relaxation induced by administration of an inhalation agent alone may be insufficient for procedures requiring profound muscle relaxation. Also, the degree of skeletal muscle relaxation may be insufficient to prevent patient movement in response to all noxious surgical stimuli during light or moderate anesthetic depth. Thus, monitoring of the degree of neuromuscular blockade is recommended to achieve adequate skeletal muscle relaxation when desired, particularly when using pharmacologic neuromuscular blocking agents, as well to ensure complete reversal when relaxation is no longer needed. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smooth muscle relaxation </strong>– All volatile inhalation agents also induce smooth muscle relaxation, which may be beneficial in certain situations. For example, uterine relaxation may be induced with administration of an inhalation anesthetic agent to facilitate extraction of retained products of conception. Other clinical effects resulting from smooth muscle relaxation may be detrimental. For example, gastrointestinal smooth muscle relaxation contributes to postoperative nausea, emesis, and ileus, while vesicoureteral smooth muscle relaxation contributes to postoperative urinary retention.</p><p></p><p class="headingAnchor" id="H2821072375"><span class="h3">Respiratory effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway reflexes </strong>– Inhalation of volatile anesthetic agents can produce airway irritation and may precipitate coughing, laryngospasm, or bronchospasm during induction of anesthesia, particularly with the more pungent agents (<a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> and <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>). This is more likely in patients who smoke or have reactive airway disease (eg, asthma, chronic obstructive pulmonary disease [COPD], cystic fibrosis, α<sub>1</sub>-antitrypsin deficiency, chronic lung disease of prematurity, or bronchopulmonary dysplasia [BPD]). The likelihood of airway complications, such as laryngospasm and bronchospasm, due to inhalation agent pungency is (from most to least likely):</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> &gt; <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> &gt; halothane &gt; <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> &gt; N<sub>2</sub>O</p></div></div><p></p><p class="bulletIndent1">In particular, high concentrations (≥1.5 MAC) of <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> are likely to cause airway irritation [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent1">During Stage II, excitement and hyperstimulation exaggerate responses to laryngeal or pharyngeal stimuli (see <a class="local">'Agitation and excitability'</a> below). These responses increase risk for laryngospasm or emesis. As transition to Stage III and deeper levels of anesthesia occurs, laryngeal and pharyngeal airway reflexes are abolished, which facilitates laryngoscopy and intubation. However, risk for aspiration is present until the airway has been secured. Hence, an inhalation anesthetic induction technique is typically avoided in patients with pre-existing risk factors for aspiration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchial effects</strong> – At higher concentrations, he potent volatile inhalation anesthetic agents are bronchodilators, decrease airway responsiveness, and attenuate bronchospasm. The bronchodilatory properties of the inhalation agents result from beta<sub>2</sub> receptor stimulation, which results in an increase in intracellular cyclic adenosine monophosphate, causing relaxation of bronchial smooth muscle [<a href="#rid9">9</a>]. In fact, volatile anesthetic agents may be used for treatment of severe status asthmaticus. <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> has the most pronounced bronchodilatory properties of the available inhalation anesthetics. Halothane was historically the agent of choice to prevent or treat bronchoconstriction, but it is no longer available in the United States. Although <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> directly relaxes airway smooth muscle at lower concentrations, higher concentrations (&gt;1.5 MAC) may increase airway resistance, particularly in patients who currently smoke [<a href="#rid8">8,10-12</a>]. (See  <a class="medical medical_review" href="/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma", section on 'Anesthetic agents'</a> and  <a class="medical medical_review" href="/d/html/94354.html" rel="external">"Anesthesia for patients with chronic obstructive pulmonary disease", section on 'Maintenance of anesthesia'</a>.)</p><p></p><p class="bulletIndent1">N<sub>2</sub>O gas is not an airway irritant, but it is also not a bronchodilator, and has little effect on airway smooth muscle [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventilation </strong>– During induction and maintenance with inhalation anesthetic agents, spontaneous ventilation is relatively preserved in Stage I, chaotic and unpredictable in Stage II, tachypneic with reduced tidal volume in Stage III, and abolished in Stage IV  (<a class="graphic graphic_figure graphicRef113985" href="/d/graphic/113985.html" rel="external">figure 7</a>). During Stages III and IV, dose-dependent respiratory depressant effects of the inhalation agents progressively shift the respiratory carbon dioxide (CO<sub>2</sub>) response curve to the right (blunting ventilatory response to hypercapnia), blunt the hypoxic ventilatory drive, and reverse hypoxic pulmonary vasoconstriction (promoting perfusion of poorly ventilated lung, thereby increasing ventilation/perfusion ratio [V/Q] mismatch, which may result in hypoxia).</p><p></p><p class="bulletIndent1">Interventions to assist or control ventilation typically become necessary, depending on the stage of anesthetic depth and the patient's clinical status.</p><p></p><p class="headingAnchor" id="H1365099616"><span class="h3">Cardiovascular effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potent volatile inhalation agents </strong>– The potent volatile anesthetics all induce myocardial depression with dose-dependent reductions in blood pressure (BP) and cardiac output, although the mechanisms for decline in BP and the degree of myocardial depression differ among agents  (<a class="graphic graphic_table graphicRef117280" href="/d/graphic/117280.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>) [<a href="#rid2">2</a>]. These effects may be beneficial in certain situations. For example, as anesthetic depth is increased with a volatile agent during induction, sympathetic stress responses are beneficially blunted in anticipation of noxious stimuli caused by laryngoscopy and endotracheal intubation.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a>, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, and <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> have primary vasodilatory properties, thereby reducing systemic vascular resistance (SVR) with relatively little initial effect on cardiac inotropy. Isoflurane and desflurane tend to produce progressive tachycardia at progressively higher concentrations, and tachycardia may be seen with sevoflurane at concentrations &gt;1.0 MAC. In particular, desflurane may induce tachycardia and hypertension due to its sympathomimetic properties, particularly with high or abruptly increased concentrations.</p><p></p><p class="bulletIndent1">Halothane preserves SVR but is a negative inotrope. In progressively higher doses, halothane also has negative chronotropic properties and may induce bradycardia or asystole, particularly in infants and young children who have relatively greater parasympathetic tone compared with adults. Also, halothane sensitizes the myocardium to catecholamines more readily than all other inhalation agents, and is thus associated with a higher incidence of ventricular and other dysrhythmias.</p><p></p><p class="bulletIndent1">Although vascular, inotropic, and chronotropic effects of the potent volatile inhalation agents differ, at high concentrations that induce Stage IV anesthetic depth (significantly above 1.0 MAC) each of these agents eventually induces cardiovascular collapse due to progressive vasodilation, bradycardia, and negative inotropy. This is one manifestation of anesthetic overdose (ie, anesthetic depth that is "too deep") (see <a class="local">'Continuum of effect: sedation to general anesthesia'</a> above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> – N<sub>2</sub>O induces few hemodynamic changes in most patients  (<a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>), in part because delivery of concentrations higher than approximately 0.75 MAC is not possible at standard temperature and pressure. However, N<sub>2</sub>O may cause mild myocardial depression and sympathetic nervous system stimulation, with mild increases in pulmonary vascular resistance  (<a class="graphic graphic_table graphicRef117280" href="/d/graphic/117280.html" rel="external">table 5</a>).</p><p></p><p class="headingAnchor" id="H2585487368"><span class="h3">Effects on cerebral physiology</span><span class="headingEndMark"> — </span>Effects of inhalation and other anesthetic agents on cerebral physiology are summarized in the table  (<a class="graphic graphic_table graphicRef105673" href="/d/graphic/105673.html" rel="external">table 7</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potent volatile inhalation agents</strong> – The potent, halogenated inhalation anesthetics (<a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, halothane) are all dose-dependent cerebral vasodilators. While they reduce cerebral metabolic rate (CMR), they can blunt cerebral autoregulation by uncoupling cerebral blood flow (CBF) and metabolism, thereby increasing CBF and intracranial pressure (ICP). At MAC values &lt;1 MAC, the net effect is a modest decrease in CBF and responsiveness to CO<sub>2</sub> is generally maintained. However, CBF increases more significantly at concentrations &gt;1 MAC. (See  <a class="medical medical_review" href="/d/html/93391.html" rel="external">"Anesthesia for craniotomy in adults", section on 'Potent inhalation agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> – N<sub>2</sub>O can increase CBF, CMR, and ICP, with generally preserved CO<sub>2</sub> responsiveness. N<sub>2</sub>O-induced changes in cerebral physiology are affected by ventilation and the administration of other anesthetic agents. (See  <a class="medical medical_review" href="/d/html/93391.html" rel="external">"Anesthesia for craniotomy in adults", section on 'Potent inhalation agents'</a>.)</p><p></p><p class="headingAnchor" id="H2041860774"><span class="h3">Agitation and excitability</span><span class="headingEndMark"> — </span>During inhalation induction of general anesthesia, a continuum of effect occurs as progressively higher doses of inhalation anesthetics are administered. Patients initially pass through Stage I, lasting from the onset of sedation until initial loss of consciousness  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 8</a>) [<a href="#rid13">13,14</a>]. Patients then pass through Stage II, characterized by delirium, excitability, and an exaggerated response to stimuli. This stage is likely to be more overt during administration of inhalation anesthetic agents rather than IV agents. Various ocular, laryngeal, and musculoskeletal responses are manifestations of Stage II  (<a class="graphic graphic_figure graphicRef113985" href="/d/graphic/113985.html" rel="external">figure 7</a>). During Stage II, patients are particularly prone to laryngospasm, emesis, and aspiration of gastric contents. Management of these risks during Stage II involves maintenance of adequate ventilation, avoidance of unnecessary stimulation, and either rapid deepening of anesthesia to reach Stage III (surgical anesthesia), or termination of anesthetic administration if appropriate (eg, awakening the patient after an unsuccessful endotracheal intubation attempt in order to perform an alternative technique such as awake flexible bronchoscopic intubation).</p><p>Agitation may also occur during emergence from general anesthesia as the patient transitions from a deeper Stage III anesthetic state through a transient phase with risk of laryngospasm and agitation (Stage II), before becoming aware and responsive to commands (Stage I)  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Airway or respiratory problems'</a> and  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Severe agitation'</a>.)</p><p class="headingAnchor" id="H547887284"><span class="h3">Postoperative nausea and vomiting</span><span class="headingEndMark"> — </span>All inhalation agents are associated with increased risk for postoperative nausea and vomiting (PONV) compared with IV anesthetic agents [<a href="#rid15">15,16</a>]. N<sub>2</sub>O is associated with a modestly higher incidence of PONV compared with other inhalation anesthetics, although this may be mitigated if standard antiemetic prophylactic measures are employed [<a href="#rid17">17,18</a>]. Prolonged administration may induce nausea and emesis based on mechanical factors since N<sub>2</sub>O diffuses into bowel gas with resultant visceral distension [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Anesthetic factors'</a>.)</p><p class="headingAnchor" id="H2576772470"><span class="h3">Reactions with carbon dioxide absorbents</span><span class="headingEndMark"> — </span>Carbon dioxide (CO<sub>2</sub>) absorbents are used in the circle breathing system of an anesthesia machine to prevent hypercapnia caused by rebreathing of exhaled CO<sub>2</sub>. These absorbents contain strong bases (eg, calcium hydroxide, sodium hydroxide [NaOH], potassium hydroxide [KOH], barium hydroxide, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> hydroxide), which react with CO<sub>2</sub> to form a carbonate. CO<sub>2</sub> absorbents also react with potent volatile anesthetic agents passing through them, particularly if the absorbent becomes desiccated. For this reason, the color of the pH indicator of the CO<sub>2</sub> absorbents is checked as part of the pre-use machine checkout to verify that the absorbent is not exhausted [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/94594.html" rel="external">"Anesthesia machines: Prevention, diagnosis, and management of malfunctions", section on 'Carbon dioxide absorbent exhaustion or toxicity'</a>.)</p><p>Reactions between volatile anesthetic agents and CO<sub>2</sub> absorbents that may result in adverse effects include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formation of carbon monoxide </strong>–<strong> </strong>CO<sub>2</sub> absorbents containing NaOH or KOH can induce production of carbon monoxide upon exposure to halogenated volatile inhalation agents, with potential risk of carbon monoxide toxicity and significant carboxyhemoglobinemia. Absorbents containing <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> hydroxide or barium hydroxide are not associated with carbon monoxide production although these CO<sub>2</sub> absorbents are more expensive. Desiccation of the absorbent, high absorbent temperature, high concentration of inhaled agent, or low fresh gas flow all increase risk of carbon monoxide production.</p><p></p><p class="bulletIndent1">Reactions of inhaled anesthetics with CO<sub>2 </sub>absorbents to induce carbon monoxide production (from most to least likely) may occur with:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> &gt; <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> &gt; halothane = <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> (Note that N<sub>2</sub>O does not induce carbon monoxide production)</p></div></div><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formation of compound A </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> interacts with the strong bases (NaOH, KOH) in some CO<sub>2</sub> absorbents to produce compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl] vinyl ether). Compound A is nephrotoxic in rats. No study has demonstrated clinically significant nephrotoxicity in humans even after prolonged administration of sevoflurane with low fresh gas flow rates, despite significant compound A production. Nevertheless, the US Food and Drug Administration (FDA) recommends use of sevoflurane with fresh gas flow rates ≥1 L/min for exposure less than one hour and ≥2 L/min for exposures more than one hour. Federal agencies in other countries have not made such recommendations, nor have professional societies.</p><p></p><p class="headingAnchor" id="H2312511985"><span class="h3">Neurotoxic effects in developing brain</span><span class="headingEndMark"> — </span>Possible neurotoxic effects of inhalation agents on the developing brain are discussed separately. (See  <a class="medical medical_review" href="/d/html/94560.html" rel="external">"Neurotoxic effects of anesthetics on the developing brain"</a>.)</p><p class="headingAnchor" id="H114336158"><span class="h3">Teratogenic effects</span><span class="headingEndMark"> — </span>Historically, there was significant concern regarding increased risk for pregnancy loss and association with congenital malformations in the offspring of pregnant women chronically exposed to low levels of inhalation agents (eg, operating room nurses, surgeons, anesthesiologists). Data are conflicting and the precise extent of risk, if any, is unclear [<a href="#rid21">21</a>]. However, these concerns resulted in requirements for fastidious scavenging and appropriate venting of inhalation agents. This is an American Society of Anesthesiologists (ASA) recommendation [<a href="#rid20">20</a>], as well as an Occupational Health and Safety Administration (OHSA) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.osha.gov%2Fwaste-anesthetic-gases%2Fworkplace-exposures-guidelines&amp;token=056QcuvsC2VNewumPRPt7jH%2B2Kb4%2FyMGKZauqGssooIsdKsNmqS7CPVsOicrGDaR%2BQ%2BCqZAIFs7Gfl72SbWz3XsvMnLpPYAJ0r5y0HV1cJ4%3D&amp;TOPIC_ID=114826" target="_blank">guideline</a> [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2217921273"><span class="h3">Malignant hyperthermia (volatile inhalation agents)</span><span class="headingEndMark"> — </span>All potent volatile inhalation anesthetic agents may induce malignant hyperthermia in susceptible individuals. (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'MH triggers'</a>.)</p><p class="headingAnchor" id="H4122019860"><span class="h1">CLINICAL USES</span></p><p class="headingAnchor" id="H918523793"><span class="h2">Induction of general anesthesia</span></p><p class="headingAnchor" id="H2512258463"><span class="h3">Inhalation induction (sevoflurane, halothane, nitrous oxide)</span><span class="headingEndMark"> — </span>Primary inhalation induction is employed in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric patients</strong> – Induction with an inhalation agent is usually preferred in infants and young children because of their fear of needles and response to the pain of a needle stick [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/106984.html" rel="external">"General anesthesia in neonates and children: Agents and techniques", section on 'Inhalation induction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult patients</strong> – Inhalation induction may be preferred in an adult if spontaneous breathing during induction is desired (eg, when intravenous [IV] access cannot be obtained, or in patients with tracheal stenosis or an intraoral, pharyngeal, or mediastinal mass causing compression of the airway). (See  <a class="medical medical_review" href="/d/html/94259.html" rel="external">"Anesthesia for patients with an anterior mediastinal mass", section on 'Airway management during induction'</a>.)</p><p></p><p class="bulletIndent1">In general, adult patient satisfaction is lower after primary inhalation induction compared with IV induction, due to the unpleasant odor of the gas [<a href="#rid24">24</a>] and a higher incidence of postoperative nausea and vomiting (PONV) [<a href="#rid24">24-26</a>]. However, development of nonpungent, nonirritant volatile anesthetics with rapid onset, particularly <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, has made inhalation induction of anesthesia via facemask a more pleasant and viable option (compared with older inhalation agents, particularly halothane) [<a href="#rid25">25</a>].</p><p></p><p>Inhalation induction of anesthesia requires a high concentration of a volatile anesthetic agent (see  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Concentration effect'</a>). Generally, the inspired concentration of a volatile anesthetic agent (eg, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>) is increased incrementally over 30 to 60 seconds during inhalation induction in order to avoid unpleasant pungency, airway irritation, and laryngospasm or bronchospasm, which is more likely when high concentrations are rapidly introduced (see <a class="local">'Respiratory effects'</a> above). <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> should not be used to induce anesthesia via facemask because it is the most pungent of the volatile anesthetics and has the highest incidence of airway irritation (coughing, salivation, breath-holding, laryngospasm) and bronchospasm, particularly at high concentrations (≥1.5 minimum alveolar concentration [MAC]) [<a href="#rid7">7,27</a>]. (See <a class="local">'Disadvantages and adverse effects'</a> below.)</p><p>Overpressurization of the anesthetic concentration or coadministration of <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> (N<sub>2</sub>O) speeds inhalation induction. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Overpressurization'</a> and  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p>Since the time required to induce anesthesia with an inhalation technique is longer (usually requiring several minutes of ventilation), this technique is not suitable for rapid sequence induction and intubation (RSII). (See  <a class="medical medical_review" href="/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia"</a>.)</p><p class="headingAnchor" id="H4241879134"><span class="h3">Use as a supplement (all inhalation agents)</span><span class="headingEndMark"> — </span>Any of the inhalation agents may be employed as a component of anesthetic induction, rather than as the primary induction agent. With this technique, initial loss of consciousness is achieved by administration of one or more IV agents (see  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents"</a>). Subsequently, an inhalation agent is administered to deepen anesthesia so that airway reflexes and sympathetic stress responses will be beneficially blunted during laryngoscopy (see <a class="local">'Respiratory effects'</a> above and <a class="local">'Cardiovascular effects'</a> above). The potent volatile agents also induce a dose-dependent decrease in skeletal muscle tone, which improves conditions for insertion of an endotracheal tube (ETT) or a supraglottic airway (SGA). (See <a class="local">'Skeletal and smooth muscle relaxation'</a> above.)</p><p class="headingAnchor" id="H3530279598"><span class="h2">Maintenance of general anesthesia (all inhalation agents)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance </strong>– All available volatile inhalation anesthetic agents (<a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, and in some countries halothane) may be used for complete maintenance of general anesthesia. Dosing of an inhalation agent to maintain general anesthesia is determined by its potency, reported as the MAC value  (<a class="graphic graphic_table graphicRef109494" href="/d/graphic/109494.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]. (See <a class="local">'MAC and MAC-awake values for inhalation agents'</a> above.)</p><p></p><p class="bulletIndent1">MAC is decreased by concurrent administration of N<sub>2</sub>O or IV anesthetic agents such as sedative-hypnotics or opioids during maintenance of general anesthesia (see <a class="local">'Influence of drug-drug interactions'</a> above and <a class="local">'Influence of patient-related factors'</a> above). Often, a volatile anesthetic agent is administered with or without N<sub>2</sub>O gas as a supplemental agent to maintain general anesthesia. Multiple medications are utilized in such balanced techniques in order to provide a combination of hypnosis, amnesia, and analgesia, and may be supplemented with a neuromuscular blocking agent (NMBA) if necessary to achieve complete immobility. (See  <a class="medical medical_review" href="/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Selection of maintenance techniques'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergence </strong>– As the surgical procedure nears completion, optimal timing for discontinuation of an inhalation agent must be planned to prepare for an emergence from general anesthesia that is neither too early nor overly delayed. Timing for discontinuation depends on the selected agent(s), doses employed, and duration of administration. Details are discussed in separate topics. (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Inhalation agents'</a> and  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Clearance'</a>.)</p><p></p><p class="headingAnchor" id="H2791077137"><span class="h2">Procedural sedation (nitrous oxide)</span><span class="headingEndMark"> — </span>N<sub>2</sub>O may be used during procedural sedation, most commonly in dental offices and other settings outside the operating room (see  <a class="medical medical_review" href="/d/html/91909.html" rel="external">"Office-based anesthesia", section on 'Selection of anesthetic agents'</a>). N<sub>2</sub>O is also used as a self-administered agent for management of pain during labor and delivery. (See  <a class="medical medical_review" href="/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery", section on 'Nitrous oxide'</a>.)</p><p>In these settings, specific advantages of the inhalation agent N<sub>2</sub>O include its availability, ease of delivery, and relative safety with usual preservation of airway patency, spontaneous ventilation, and cardiovascular function, compared with use of various IV agents (eg, sedative-hypnotics, anxiolytics, opioids, and other anesthetic adjuvant agents) (see <a class="local">'Advantages'</a> below). Disadvantages include inability to deliver concentrations greater than approximately 75 percent MAC at standard clinical temperature and pressure. (See <a class="local">'MAC and MAC-awake values for inhalation agents'</a> above and <a class="local">'Disadvantages and adverse effects'</a> below.)</p><p>In remote settings, lack of scavenging and appropriate venting is a potential disadvantage. Also, anesthesia care teams may not be available to manage complications or provide a deeper level of anesthesia if necessary.</p><p class="headingAnchor" id="H4283662242"><span class="h1">SPECIFIC INHALATION ANESTHETIC AGENTS</span><span class="headingEndMark"> — </span>There are properties shared by all volatile inhalation anesthetic agents (see <a class="local">'Clinical effects'</a> above). However, specific advantages, disadvantages, and adverse effects differ among the available potent volatile agents as noted below.</p><p class="headingAnchor" id="H670378431"><span class="h2">Sevoflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> is supplied as a colorless bottled liquid that readily evaporates at standard temperature and pressure. It is delivered via a vaporizer mounted on the anesthesia machine. Its properties are noted in the table  (<a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>).</p><p class="headingAnchor" id="H2689551108"><span class="h3">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Sweet-smelling, low pungency. Thus, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> is useful for inhalation induction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low blood:gas partition coefficient, with consequent rapid uptake and induction of general anesthesia as well as rapid clearance and emergence. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Blood:gas partition coefficient'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderately high potency with a moderately low minimum alveolar concentration (MAC). (See <a class="local">'MAC and MAC-awake values for inhalation agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of significant negative chronotropic or negative inotropic effects at concentrations near MAC, modest vasodilatory properties.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Little effect on cerebral autoregulation across a range of concentrations [<a href="#rid28">28</a>]. (See <a class="local">'Effects on cerebral physiology'</a> above.)</p><p></p><p class="headingAnchor" id="H2575612420"><span class="h3">Disadvantages and adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span>High cost, particularly with use during longer procedures. Compared with other potent volatile anesthetic agents, expense is higher because slightly higher fresh gas flows are employed (typically 1 to 2 L/minute of oxygen and/or air) to avoid formation of compound A. (See <a class="local">'Reactions with carbon dioxide absorbents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Theoretical risk of compound A-associated nephropathy. However, compound A is not generated by newer carbon dioxide absorbents. (See <a class="local">'Reactions with carbon dioxide absorbents'</a> above.)</p><p></p><p class="headingAnchor" id="H439337827"><span class="h3">Typical uses</span><span class="headingEndMark"> — </span>Overall, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> is the most commonly used potent volatile inhaled agent in industrialized countries.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction</strong> – <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> is the most frequently used inhaled agent for induction of anesthesia (because of its minimal odor, lack of pungency, and potent bronchodilatory characteristics [<a href="#rid23">23-27,29,30</a>]. Sevoflurane has many characteristics of the ideal induction agent, including relatively rapid onset due to its low tissue and blood solubility. The time to loss of consciousness may be as little as 60 seconds if a high concentration of sevoflurane (eg, 4 to 8 percent) is delivered via a facemask [<a href="#rid23">23,31,32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> is also frequently selected for maintenance of anesthesia because more rapid changes in anesthetic depth are possible during painful interventions compared with more soluble agents such as <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, and more rapid recovery occurs during emergence after a short procedure. However, for procedures lasting longer than approximately two hours, emergence times are similar after administration of sevoflurane or isoflurane because of their nearly identical fat solubilities, which allow similar accumulation in tissues during prolonged administration. This is in contrast to <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, which is markedly less soluble in fat, accumulates less in tissues even after prolonged administration, and is associated with more rapid emergence in most settings [<a href="#rid33">33</a>]. (See <a class="local">'Advantages'</a> below.)</p><p></p><p class="headingAnchor" id="H1665285148"><span class="h2">Desflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> is supplied as a colorless bottled liquid that does not readily evaporate at standard temperature and pressure. Desflurane is delivered by an electric heated vaporizer mounted on the anesthesia machine. Its properties are noted in the table  (<a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>).</p><p class="headingAnchor" id="H432712117"><span class="h3">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Very low blood:gas partition coefficient, with consequent very rapid uptake and induction of general anesthesia, as well as very rapid clearance and emergence. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Blood:gas partition coefficient'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very low oil:gas partition coefficient with consequent minimal uptake into adipose tissue. Due to its absence of accumulation in tissues because of its low solubility in oil, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> is particularly advantageous for patients with obesity or sleep apnea [<a href="#rid34">34-36</a>]. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Oil:gas partition coefficient/potency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undergoes the least metabolism of all potent volatile agents. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Metabolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, an advantage for <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> is safety during use with low fresh gas flows in the breathing circuit. (See <a class="local">'Sevoflurane'</a> above.).</p><p></p><p class="headingAnchor" id="H564223405"><span class="h3">Disadvantages and adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span>Very high pungency. <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> is the most pungent of the volatile anesthetics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marked airway irritation (eg, coughing, salivation, breath-holding, laryngospasm), particularly with administration at concentrations ≥1.5 MAC, due to high pungency. (See <a class="local">'Respiratory effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high incidence of coughing during emergence compared with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> [<a href="#rid7">7,27,35,36</a>]. (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Airway or respiratory problems'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For these reasons, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> is not suitable for inhalation induction of anesthesia (see <a class="local">'Inhalation induction (sevoflurane, halothane, nitrous oxide)'</a> above) [<a href="#rid7">7,27</a>]. Also, desflurane is not ideal for patients who smoke or have reactive airway disease (eg, asthma, chronic obstructive pulmonary disease [COPD], cystic fibrosis, α<sub>1</sub>-antitrypsin deficiency, chronic lung disease of prematurity, or bronchopulmonary dysplasia [BPD]). Although desflurane at lower concentrations (&lt;1.5 MAC) has been used during maintenance of anesthesia for patients at risk for bronchospasm, higher concentrations may increase airway resistance [<a href="#rid8">8,10-12</a>]. (See  <a class="medical medical_review" href="/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma", section on 'Maintenance of anesthesia'</a> and  <a class="medical medical_review" href="/d/html/94354.html" rel="external">"Anesthesia for patients with chronic obstructive pulmonary disease", section on 'Maintenance of anesthesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia and hypertension due to sympathomimetic properties, particularly with administration of high or abruptly increased inspired concentrations [<a href="#rid37">37</a>]. With continued administration, hypertension tends to resolve at steady state, although tachycardia may persist. These properties also limit use of <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> as a primary agent for induction of general anesthesia, since any inhalation agent must be rapidly increased to produce a high enough concentration to induce unconsciousness in a previously awake patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since tachycardia may persist, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> is not ideal for patients with significant ischemic heart disease, hypertrophic obstructive cardiomyopathy, aortic or mitral stenosis, or other patients for whom tachycardia is undesirable. If desflurane is used during maintenance of anesthesia for such patients, high concentrations and rapid increases in concentration are avoided. (See  <a class="medical medical_review" href="/d/html/90616.html" rel="external">"Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high cost, particularly during long procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for a specialized electric heated vaporizer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low potency with high MAC.</p><p></p><p class="headingAnchor" id="H332571764"><span class="h3">Typical uses</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> is frequently selected for maintenance of anesthesia, particularly during short procedures, because very rapid changes in anesthetic depth are possible during painful interventions, and very rapid recovery occurs during emergence. Due to ease of titration, rapidity of recovery, and minimal residual effects, desflurane is particularly advantageous for older patients and those with obesity or sleep apnea [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H2453040825"><span class="h2">Isoflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a> is supplied as a colorless bottled liquid that readily evaporates at standard temperature and pressure. It is delivered via a vaporizer mounted on the anesthesia machine. Its properties are noted in the table  (<a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>).</p><p class="headingAnchor" id="H1839880865"><span class="h3">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>High potency with low MAC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very low cost, particularly with use during long procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Little effect on cerebral autoregulation at concentrations &lt;1 MAC [<a href="#rid38">38,39</a>].</p><p></p><p class="headingAnchor" id="H570546923"><span class="h3">Disadvantages and adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span>High pungency, which limits its utility as a primary agent for inhalation induction of anesthesia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderately high blood:gas partition coefficient, with consequent slow uptake and induction of general anesthesia, compared with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> or <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>. This further limits use of <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> during induction (except as a supplemental agent). (See <a class="local">'Use as a supplement (all inhalation agents)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High solubility in fat, associated with prolonged emergence particularly after prolonged procedures because of accumulation in tissues. This property limits its use in procedures of prolonged duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive chronotropy with associated tachycardia that may be clinically significant when tachycardia is undesirable (eg, ischemic heart disease). (See  <a class="medical medical_review" href="/d/html/90616.html" rel="external">"Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild negative inotropy, vasodilatory properties.</p><p></p><p class="headingAnchor" id="H3873546437"><span class="h3">Typical uses</span></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance – <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a> is frequently selected for maintenance of anesthesia, particularly if the anticipated duration of the procedure is long, because it is inexpensive, widely available, and the most potent of the volatile anesthetics. Its unpleasant pungency limits its utility as a primary inhalation agent during induction, although it may be employed as a supplemental agent after administration of IV induction agents in order to deepen and maintain anesthesia.</p><p></p><p class="bulletIndent1">As with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> has high solubility in fat and is associated with prolonged emergence particularly after prolonged procedures because of accumulation in tissues. Thus, timing for discontinuation of isoflurane must be carefully planned as the surgical procedure is nearing completion. (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Discontinue anesthetic agents'</a>.)</p><p></p><p class="headingAnchor" id="H4266242853"><span class="h2">Halothane</span><span class="headingEndMark"> — </span>Halothane is supplied as a bottled liquid that readily evaporates at standard temperature and pressure. It is delivered via a vaporizer mounted on the anesthesia machine. Properties of halothane are noted in the table  (<a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>).</p><p>Stability of halothane is maintained with the addition of 0.01 percent thymol, which may accumulate in the vaporizer to eventually impart a yellow color to the remaining liquid. Development of such discoloration indicates that the halothane vaporizer should be drained and cleaned.</p><p class="headingAnchor" id="H1889991108"><span class="h3">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Sweet-smelling gas with only moderate pungency. Thus, halothane is often used for inhalation induction in resource-challenged countries where it remains available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high potency with very low MAC.</p><p></p><p class="headingAnchor" id="H1181541305"><span class="h3">Disadvantages and adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span>Very high solubility in blood, tissue, and oil, with consequent very slow uptake and induction of general anesthesia, as well as very slow clearance and emergence. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Blood:gas partition coefficient'</a> and  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Brain:blood partition coefficient'</a> and  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Oil:gas partition coefficient/potency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Negative inotropy and significant negative chronotropy, even if administered at relatively low concentrations. At high concentrations, halothane may induce severe bradycardia or asystole.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High incidence of ventricular and other dysrhythmias due to sensitization of the myocardium to catecholamines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undergoes greater hepatic metabolism than all other inhalation agents, with associated risks for both cytotoxic and autoimmune hepatotoxicity and halothane hepatitis [<a href="#rid40">40-42</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Halothane hepatotoxicity</strong> – Hepatotoxicity can occur with or without prior halothane exposure. Postoperative elevation in serum aminotransferases has been observed in 20 to 30 percent of patients receiving halothane [<a href="#rid43">43</a>]. Most patients are asymptomatic, although a subset develops symptoms of mild clinical hepatitis characterized by nausea, lethargy, and fever. The aminotransferases remain elevated for one to two weeks following exposure and resolve without treatment [<a href="#rid44">44</a>]. This reaction is generally considered a non-immune phenomenon, and recovery is the rule.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Halothane hepatitis</strong> – A rarer and more unpredictable occurrence is an acute severe hepatitis "halothane hepatitis," with potential development of hepatic necrosis and acute liver failure that is often fatal. The incidence is 1 in 6000 to 1 in 15,000 following a single exposure to the anesthetic, and increases to approximately 1 in 1000 following multiple exposures, particularly if they occur within 28 days of prior exposure [<a href="#rid45">45</a>]. Other risk factors for severe hepatotoxicity may include short intervals between exposures, female sex (2:1), age greater than 40 years (80 percent of cases), obesity, underlying liver dysfunction, and a genetic predisposition to hepatitis [<a href="#rid46">46-48</a>].</p><p></p><p class="bulletIndent2">Symptoms generally develop approximately two days to three weeks after exposure. Approximately 75 percent of patients present with a fever and may complain of anorexia, nausea, myalgias, arthralgias, and rash [<a href="#rid49">49</a>]. Eosinophilia occurs in approximately 40 percent of cases, suggesting that toxicity is immunoallergic [<a href="#rid50">50</a>]. Tender hepatomegaly and jaundice are common. Some patients present with acute liver failure, markedly elevated serum aminotransferases and prothrombin time, and possibly hepatic encephalopathy.</p><p></p><p class="bulletIndent2">Halothane-associated hepatitis is rare in children, occurring in between 1 in 82,000 and 1 in 200,000 [<a href="#rid51">51,52</a>]. The reason for the lower incidence of halothane-associated hepatitis observed in children is unclear [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H1471095372"><span class="h3">Typical uses</span><span class="headingEndMark"> — </span>Halothane is no longer commercially available in North America, Europe, and many other countries due to its adverse effects (particularly the possibility of halothane hepatitis), and the development of newer inhalation agents that have replaced it, in particular <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>. However, due to its low cost, halothane is still used for both induction and maintenance of general anesthesia in resource-challenged countries, particularly in children.</p><p class="headingAnchor" id="H72857815"><span class="h2">Nitrous oxide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> (N<sub>2</sub>O) is supplied as a pressurized gas in equilibrium with its liquid phase that is delivered via a flow meter on the anesthesia machine. (See  <a class="medical medical_review" href="/d/html/94594.html" rel="external">"Anesthesia machines: Prevention, diagnosis, and management of malfunctions", section on 'Compressed gas flowmeter malfunction'</a>.)</p><p class="headingAnchor" id="H3010090094"><span class="h3">Advantages</span></p><p class="bulletIndent1"><span class="glyph">●</span>Slightly sweet-smelling gas, with no pungency and no potential for airway irritation. Thus, N<sub>2</sub>O is useful for inhalation induction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very low blood:gas partition coefficient, with consequent very rapid rate of rise of its alveolar concentration and onset of anesthetic effect. Changes in anesthetic depth during maintenance are also very rapid. Furthermore, addition of N<sub>2</sub>O near the end of surgery may speed recovery from anesthesia, particularly if a volatile agent with a high blood:gas partition coefficient is being administered (eg, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, halothane). In one study, addition of N<sub>2</sub>O during the last 30 minutes of an isoflurane-based anesthetic reduced the time to extubation by approximately two minutes (2.0 minutes, 95% CI 0.6-3.4), as well as reducing time to eye opening, following commands, and being oriented [<a href="#rid54">54</a>]. Presumably, faster recovery occurred because the anesthesia provider could reduce the administered concentration of isoflurane, as well as taking advantage of the "second-gas" effect of N<sub>2</sub>O, as noted in the next bullet. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Blood:gas partition coefficient'</a> and <a class="local">'Disadvantages and adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increases speed of anesthetic onset and offset when coadministered with any potent volatile inhalation agent, compared with administration of the potent agent alone. This is due to a phenomenon termed the "second gas" effect. Notably, second gas effects with N<sub>2</sub>O are more pronounced with more soluble volatile anesthetics (eg, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, halothane). (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analgesic and anxiolytic properties, which typically decrease requirements for the primary inhalation agent and/or for IV anesthetic agents. (See <a class="local">'Influence of drug-drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced likelihood of postoperative opioid-induced hyperalgesia and potentially reduced incidence of chronic postsurgical pain [<a href="#rid55">55,56</a>]. Results of the Enhanced Neuro Imaging Genetics through Meta-Analysis (ENIGMA) multicenter study of N<sub>2</sub>O as a component of balanced general anesthesia suggested a decreased incidence of chronic pain in patients receiving N<sub>2</sub>O [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Negligible hemodynamic effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undergoes no significant biotransformation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low cost.</p><p></p><p class="headingAnchor" id="H1206995058"><span class="h3">Disadvantages and adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span>Very low potency and consequent inability to deliver concentrations greater than approximately 0.75 MAC at standard clinical temperature and pressure. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Oil:gas partition coefficient/potency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Association with a modestly higher incidence of postoperative nausea and vomiting (PONV) compared with other inhalation anesthetic agents, although this may be mitigated if antiemetic prophylactic measures are employed [<a href="#rid17">17,18</a>]. Diffusion into bowel gas with associated visceral distension may increase risk of PONV, particularly after prolonged use. However, not all studies have noted increased risk of PONV with short-term administration of N<sub>2</sub>O, even if no prophylactic antiemetic agents were administered [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Anesthetic factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuses into any gas-filled cavity. Thus, administration is avoided in patients with possible pre-existing bowel distention, increased middle ear pressure, pneumothorax, pneumoperitoneum, pneumocephalus, intraocular gas, or venous air embolism [<a href="#rid2">2,17,18</a>]. Further gaseous distension of such spaces has potentially significant adverse consequences (eg, nausea with emesis, tension pneumothorax, increased intracranial pressure (ICP), vision loss, expansion of entrapped intravascular air).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible increased incidence of postoperative atelectasis in patients with pre-existing poor pulmonary function. In one systematic review, patients undergoing N<sub>2</sub>O-based techniques had an increased incidence of atelectasis (odds ratio [OR] 1.57, 95% CI 1.18-2.10), but there were no effects on mortality, pneumonia, or other adverse postoperative outcomes [<a href="#rid17">17</a>]. Thus, the clinical relevance of this finding is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential for transient diffusion hypoxia with discontinuation of N<sub>2</sub>O at low inspired oxygen concentrations. Upon discontinuation, bulk transfer of N<sub>2</sub>O gas into the alveolus displaces oxygen and decreases alveolar oxygen concentration, potentially inducing desaturation. Such diffusion hypoxia may be prevented by delivery of high inspired oxygen concentration for several minutes before and after discontinuing N<sub>2</sub>O. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential for fire hazard. Although not itself flammable, N<sub>2</sub>O supports combustion, and a potential fire hazard exists (particularly in combination with bowel gas). (See  <a class="medical medical_review" href="/d/html/94592.html" rel="external">"Fire safety in the operating room", section on 'Nitrous oxide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild myocardial depression and sympathetic nervous system stimulation, with mildly increased pulmonary vascular resistance  (<a class="graphic graphic_table graphicRef117280" href="/d/graphic/117280.html" rel="external">table 5</a>). Although N<sub>2</sub>O is typically avoided in patients with severe cardiomyopathy and pulmonary hypertension, it has not been associated with increased risk of cardiac complications after noncardiac surgery [<a href="#rid15">15,17,57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>N<sub>2</sub>O should be avoided in patients with disorders of B12, folate, or methionine synthesis or metabolism.</p><p></p><p class="bulletIndent1">N<sub>2</sub>O inactivates vitamin B<sub>12</sub>. In patients who have pre-existing vitamin B<sub>12</sub> deficiency, this may result in neurotoxicity with sensory neuropathy, myelopathy, and encephalopathy. Recovery may be slow and incomplete even after treatment with vitamin B<sub>12</sub>.</p><p></p><p class="bulletIndent1">Vitamin B<sub>12</sub> is an essential cofactor for methylenetetrahydrofolate reductase (MTHFR; ie, methionine synthetase), an enzyme critical in both folate (vitamin B<sub>9</sub>) and homocysteine/methionine pathways. N<sub>2</sub>O-induced oxidation of vitamin B<sub>12</sub> inhibits methionine synthetase activity [<a href="#rid2">2</a>], thereby impairing synthesis of both tetrahydrofolate and methionine. Reduced tetrahydrofolate synthesis impairs purine and thymidine synthesis and may cause immunosuppression [<a href="#rid59">59</a>]. Reduced methionine synthesis and associated increased levels of homocysteine also theoretically increase risk for thrombosis and may lead to endothelial dysfunction [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some potential for abuse because of its analgesic, anxiolytic, and euphoric properties.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Association with teratogenic effects in animal models, although this has not been demonstrated in humans. However, adequacy of scavenging should be ensured during use near potentially pregnant health care workers in operating rooms or other settings [<a href="#rid61">61,62</a>]. (See <a class="local">'Teratogenic effects'</a> above.)</p><p></p><p class="headingAnchor" id="H456926750"><span class="h3">Typical uses</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction</strong> – N<sub>2</sub>O gas is commonly used as an adjuvant agent during inhalation induction of general anesthesia. Due to its very low solubility in blood, the rate of rise of its alveolar concentration occurs very rapidly during inhalation induction. Since N<sub>2</sub>O has low potency it is rarely used as the sole anesthetic agent (MAC value is 104 percent); however, it is commonly coadministered with a potent volatile inhalation agent because its "second gas" effect hastens the onset of anesthesia and increases in anesthetic depth [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – N<sub>2</sub>O gas is also commonly used during maintenance of general anesthesia as an adjuvant to a volatile anesthetic and/or IV anesthetic agents because it is widely available and inexpensive [<a href="#rid63">63</a>]. Administration of N<sub>2</sub>O increases anesthetic depth, resulting in decreased dosing of other anesthetic agents. However, N<sub>2</sub>O cannot be used as a sole agent to maintain anesthesia because of its low potency (MAC value is 104 percent) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedural sedation</strong> – N<sub>2</sub>O may be used during procedural sedation or as a self-administered agent for management of pain during labor and delivery.</p><p></p><p>N<sub>2</sub>O use is avoided in patients with pre-existing bowel distention, increased middle ear pressure, pneumothorax, pneumoperitoneum, pneumocephalus, intraocular gas, or venous air embolism [<a href="#rid2">2,17,18</a>]. Also, N<sub>2</sub>O is typically avoided in patients with cardiomyopathy and pulmonary hypertension because it causes mild myocardial depression and sympathetic nervous system stimulation with increases in pulmonary vascular resistance. Furthermore, N<sub>2</sub>O use is generally avoided in patients with vitamin B<sub>12</sub> deficiency or those with other MTHFR deficiencies.</p><p class="headingAnchor" id="H162973896"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-dependent clinical effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sedation and anesthesia</strong> – The primary clinical effect of inhalation anesthetic agents is dose-dependent sedation progressing to complete general anesthesia with hypnosis, amnesia, analgesia, akinesia, and autonomic and somatic block  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef109909" href="/d/graphic/109909.html" rel="external">table 9</a>). (See <a class="local">'Continuum of effect: sedation to general anesthesia'</a> above.)</p><p></p><p class="bulletIndent2">The minimum alveolar concentration (MAC) value is the concentration of an inhalation agent in the alveoli required to prevent movement in response to a noxious stimulus in 50 percent of subjects  (<a class="graphic graphic_figure graphicRef117701" href="/d/graphic/117701.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef117702" href="/d/graphic/117702.html" rel="external">figure 3</a> and <a class="graphic graphic_figure graphicRef113991" href="/d/graphic/113991.html" rel="external">figure 1</a>), while the MAC-awake (also termed MAC-aware) value is the concentration of an inhalation agent in the alveoli at which 50 percent of patients will not respond to a verbal or non-noxious tactile stimulus  (<a class="graphic graphic_table graphicRef109424" href="/d/graphic/109424.html" rel="external">table 1</a>). MAC values differ for each inhalation agent, and are measures of anesthetic potency  (<a class="graphic graphic_table graphicRef109494" href="/d/graphic/109494.html" rel="external">table 2</a>). (See <a class="local">'MAC and MAC-awake values for inhalation agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Respiratory effects</strong> – Respiratory depression and suppression of airway reflexes. (See <a class="local">'Respiratory effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular effects</strong> – Myocardial depression with decreased blood pressure  (<a class="graphic graphic_table graphicRef117280" href="/d/graphic/117280.html" rel="external">table 5</a>). (See <a class="local">'Cardiovascular effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cerebral effects</strong> – Decreased cerebral metabolic rate with increased cerebral blood flow  (<a class="graphic graphic_table graphicRef105673" href="/d/graphic/105673.html" rel="external">table 7</a>). (See <a class="local">'Effects on cerebral physiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Effects on muscle tone</strong> – Decreased skeletal and smooth muscle tone, as well<strong> as </strong>bronchial and uterine relaxation. (See <a class="local">'Skeletal and smooth muscle relaxation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other clinical effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agitation and excitability</strong> – Transient delirium and exaggerated responses to stimuli during Stage II as anesthesia is being induced (Stage II  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 8</a> and <a class="graphic graphic_figure graphicRef113985" href="/d/graphic/113985.html" rel="external">figure 7</a>)), with increased risk of laryngospasm, emesis, and aspiration of gastric contents. (See <a class="local">'Agitation and excitability'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative nausea and vomiting</strong> – Increased risk compared with intravenous alternatives. (See <a class="local">'Postoperative nausea and vomiting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurotoxic and teratogenic effects</strong> – All have possible neurotoxic and teratogenic effects. Malignant hyperthermia can be induced in susceptible individuals. (See <a class="local">'Neurotoxic effects in developing brain'</a> above and <a class="local">'Teratogenic effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Malignant hyperthermia</strong> – All potent volatile inhalation anesthetic agents may induce malignant hyperthermia in susceptible individuals. (See <a class="local">'Malignant hyperthermia (volatile inhalation agents)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical uses</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General anesthesia</strong> – Inhalation agents may be used as primary agents to induce general anesthesia (<a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> or halothane with or without <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> [N<sub>2</sub>O]), or as supplemental agents to induce and/or maintain anesthesia (all inhalation agents). (See <a class="local">'Induction of general anesthesia'</a> above and <a class="local">'Maintenance of general anesthesia (all inhalation agents)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Procedural sedation</strong> – N<sub>2</sub>O is occasionally used during procedural sedation or as a self-administered agent for management of pain during labor and delivery. (See <a class="local">'Procedural sedation (nitrous oxide)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages and disadvantages</strong> – The potent volatile agents differ in their specific advantages, disadvantages, and adverse effects, as described above  (<a class="graphic graphic_table graphicRef113972" href="/d/graphic/113972.html" rel="external">table 6</a>) (see <a class="local">'Specific inhalation anesthetic agents'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> (See <a class="local">'Sevoflurane'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> (See <a class="local">'Desflurane'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a> (See <a class="local">'Isoflurane'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Halothane (See <a class="local">'Halothane'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> (See <a class="local">'Nitrous oxide'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eger EI 2nd, Saidman LJ, Brandstater B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 1965; 26:756.</a></li><li><a class="nounderline abstract_t">Torri G. Inhalation anesthetics: a review. Minerva Anestesiol 2010; 76:215.</a></li><li><a class="nounderline abstract_t">Hendrickx JF, Eger EI 2nd, Sonner JM, Shafer SL. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494.</a></li><li><a class="nounderline abstract_t">Aranake A, Mashour GA, Avidan MS. Minimum alveolar concentration: ongoing relevance and clinical utility. Anaesthesia 2013; 68:512.</a></li><li><a class="nounderline abstract_t">Wu Y, Jin S, Zhang L, et al. Minimum Alveolar Concentration-Awake of Sevoflurane Is Decreased in Patients With End-Stage Renal Disease. Anesth Analg 2019; 128:77.</a></li><li><a class="nounderline abstract_t">Berger M, Schenning KJ, Brown CH 4th, et al. Best Practices for Postoperative Brain Health: Recommendations From the Fifth International Perioperative Neurotoxicity Working Group. Anesth Analg 2018; 127:1406.</a></li><li><a class="nounderline abstract_t">de Oliveira GS Jr, Girao W, Fitzgerald PC, McCarthy RJ. The effect of sevoflurane versus desflurane on the incidence of upper respiratory morbidity in patients undergoing general anesthesia with a Laryngeal Mask Airway: a meta-analysis of randomized controlled trials. J Clin Anesth 2013; 25:452.</a></li><li><a class="nounderline abstract_t">Nyktari V, Papaioannou A, Volakakis N, et al. Respiratory resistance during anaesthesia with isoflurane, sevoflurane, and desflurane: a randomized clinical trial. Br J Anaesth 2011; 107:454.</a></li><li><a class="nounderline abstract_t">Rooke GA, Choi JH, Bishop MJ. The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. Anesthesiology 1997; 86:1294.</a></li><li><a class="nounderline abstract_t">Dikmen Y, Eminoglu E, Salihoglu Z, Demiroluk S. Pulmonary mechanics during isoflurane, sevoflurane and desflurane anaesthesia. Anaesthesia 2003; 58:745.</a></li><li><a class="nounderline abstract_t">Satoh JI, Yamakage M, Kobayashi T, et al. Desflurane but not sevoflurane can increase lung resistance via tachykinin pathways. Br J Anaesth 2009; 102:704.</a></li><li><a class="nounderline abstract_t">Goff MJ, Arain SR, Ficke DJ, et al. Absence of bronchodilation during desflurane anesthesia: a comparison to sevoflurane and thiopental. Anesthesiology 2000; 93:404.</a></li><li><a class="nounderline abstract_t">Hewer CL. THE STAGES AND SIGNS OF GENERAL ANAESTHESIA. Br Med J 1937; 2:274.</a></li><li class="breakAll">Guelrud AE. Inhalation anesthesia: A fundamental guide, 2nd ed, The Macmillan Company, New York 1951.</li><li><a class="nounderline abstract_t">Myles PS, Leslie K, Chan MT, et al. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. Lancet 2014; 384:1446.</a></li><li><a class="nounderline abstract_t">Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350:2441.</a></li><li><a class="nounderline abstract_t">Sun R, Jia WQ, Zhang P, et al. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. Cochrane Database Syst Rev 2015; :CD008984.</a></li><li><a class="nounderline abstract_t">Myles PS, Chan MT, Kasza J, et al. Severe Nausea and Vomiting in the Evaluation of Nitrous Oxide in the Gas Mixture for Anesthesia II Trial. Anesthesiology 2016; 124:1032.</a></li><li><a class="nounderline abstract_t">Fernández-Guisasola J, Gómez-Arnau JI, Cabrera Y, del Valle SG. Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis. Anaesthesia 2010; 65:379.</a></li><li class="breakAll">www.asahq.org/resources/clinical-information/2008-asa-recommendations-for-pre-anesthesia-checkout (Accessed on March 19, 2017).</li><li><a class="nounderline abstract_t">Burm AG. Occupational hazards of inhalational anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17:147.</a></li><li class="breakAll">Anesthetic Gases: Guidelines for Workplace Exposures. Occupational Safety and Health Administration. https://www.osha.gov/dts/osta/anestheticgases/index.html (Accessed on July 19, 2017).</li><li><a class="nounderline abstract_t">Sigston PE, Jenkins AM, Jackson EA, et al. Rapid inhalation induction in children: 8% sevoflurane compared with 5% halothane. Br J Anaesth 1997; 78:362.</a></li><li><a class="nounderline abstract_t">Thwaites A, Edmends S, Smith I. Inhalation induction with sevoflurane: a double-blind comparison with propofol. Br J Anaesth 1997; 78:356.</a></li><li><a class="nounderline abstract_t">Joshi GP. Inhalational techniques in ambulatory anesthesia. Anesthesiol Clin North America 2003; 21:263.</a></li><li><a class="nounderline abstract_t">Suzuki KS, Oohata M, Mori N. Multiple-deep-breath inhalation induction with 5% sevoflurane and 67% nitrous oxide: comparison with intravenous injection of propofol. J Anesth 2002; 16:97.</a></li><li><a class="nounderline abstract_t">White PF, Tang J, Wender RH, et al. Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing. Anesth Analg 2009; 109:387.</a></li><li><a class="nounderline abstract_t">Dagal A, Lam AM. Cerebral autoregulation and anesthesia. Curr Opin Anaesthesiol 2009; 22:547.</a></li><li><a class="nounderline abstract_t">Mostafa SM, Atherton AM. Sevoflurane for difficult tracheal intubation. Br J Anaesth 1997; 79:392.</a></li><li class="breakAll">Thomas Ebert and Larry Lindenbaum. Inhaled Anesthetics. In: Clinical Anesthesia, Seventh, Paul G. Barash (Ed), Lippincott Williams Wilkins, Philadelphia 2013. p.447-477.</li><li><a class="nounderline abstract_t">Lejus C, Bazin V, Fernandez M, et al. Inhalation induction using sevoflurane in children: the single-breath vital capacity technique compared to the tidal volume technique*. Anaesthesia 2006; 61:535.</a></li><li><a class="nounderline abstract_t">Boonmak P, Boonmak S, Pattanittum P. High initial concentration versus low initial concentration sevoflurane for inhalational induction of anaesthesia. Cochrane Database Syst Rev 2016; :CD006837.</a></li><li><a class="nounderline abstract_t">Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog 2008; 55:124.</a></li><li><a class="nounderline abstract_t">McKay RE, Malhotra A, Cakmakkaya OS, et al. Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane. Br J Anaesth 2010; 104:175.</a></li><li><a class="nounderline abstract_t">Jakobsson J. Desflurane: a clinical update of a third-generation inhaled anaesthetic. Acta Anaesthesiol Scand 2012; 56:420.</a></li><li><a class="nounderline abstract_t">Dexter F, Bayman EO, Epstein RH. Statistical modeling of average and variability of time to extubation for meta-analysis comparing desflurane to sevoflurane. Anesth Analg 2010; 110:570.</a></li><li><a class="nounderline abstract_t">Weiskopf RB, Moore MA, Eger EI 2nd, et al. Rapid increase in desflurane concentration is associated with greater transient cardiovascular stimulation than with rapid increase in isoflurane concentration in humans. Anesthesiology 1994; 80:1035.</a></li><li><a class="nounderline abstract_t">Strebel S, Lam AM, Matta B, et al. Dynamic and static cerebral autoregulation during isoflurane, desflurane, and propofol anesthesia. Anesthesiology 1995; 83:66.</a></li><li><a class="nounderline abstract_t">Aladj LJ, Croughwell N, Smith LR, Reves JG. Cerebral blood flow autoregulation is preserved during cardiopulmonary bypass in isoflurane-anesthetized patients. Anesth Analg 1991; 72:48.</a></li><li><a class="nounderline abstract_t">Otedo AE. Halothane induced hepatitis: case report. East Afr Med J 2004; 81:538.</a></li><li><a class="nounderline abstract_t">Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:755.</a></li><li><a class="nounderline abstract_t">Kharasch ED. Adverse drug reactions with halogenated anesthetics. Clin Pharmacol Ther 2008; 84:158.</a></li><li><a class="nounderline abstract_t">Safari S, Motavaf M, Seyed Siamdoust SA, Alavian SM. Hepatotoxicity of halogenated inhalational anesthetics. Iran Red Crescent Med J 2014; 16:e20153.</a></li><li><a class="nounderline abstract_t">Wright R, Eade OE, Chisholm M, et al. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975; 1:817.</a></li><li><a class="nounderline abstract_t">Habibollahi P, Mahboobi N, Esmaeili S, et al. Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis. Hepat Mon 2011; 11:3.</a></li><li><a class="nounderline abstract_t">Stachnik J. Inhaled anesthetic agents. Am J Health Syst Pharm 2006; 63:623.</a></li><li><a class="nounderline abstract_t">Dugan CM, MacDonald AE, Roth RA, Ganey PE. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 2010; 333:364.</a></li><li><a class="nounderline abstract_t">Fleifel WAN. Effects of halothane anesthesia on patients with abnormal liver function tests. J Basrah Res ((Sciences)) 2011; 4:84.</a></li><li><a class="nounderline abstract_t">Holt C, Csete M, Martin P. Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroenterol Clin North Am 1995; 24:853.</a></li><li><a class="nounderline abstract_t">Kenna JG, Neuberger JM. Immunopathogenesis and treatment of halothane hepatitis. Clin Immunother 1995; 3:108.</a></li><li><a class="nounderline abstract_t">Warner LO, Beach TP, Garvin JP, Warner EJ. Halothane and children: the first quarter century. Anesth Analg 1984; 63:838.</a></li><li><a class="nounderline abstract_t">Kenna JG, Neuberger J, Mieli-Vergani G, et al. Halothane hepatitis in children. Br Med J (Clin Res Ed) 1987; 294:1209.</a></li><li><a class="nounderline abstract_t">Wark H, Earl J, Chau DD, Overton J. Halothane metabolism in children. Br J Anaesth 1990; 64:474.</a></li><li><a class="nounderline abstract_t">Mraovic B, Simurina T, Gan TJ. Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial. Can J Anaesth 2018; 65:162.</a></li><li><a class="nounderline abstract_t">Echevarría G, Elgueta F, Fierro C, et al. Nitrous oxide (N(2)O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans. Br J Anaesth 2011; 107:959.</a></li><li><a class="nounderline abstract_t">Chan MT, Wan AC, Gin T, et al. Chronic postsurgical pain after nitrous oxide anesthesia. Pain 2011; 152:2514.</a></li><li><a class="nounderline abstract_t">Imberger G, Orr A, Thorlund K, et al. Does anaesthesia with nitrous oxide affect mortality or cardiovascular morbidity? A systematic review with meta-analysis and trial sequential analysis. Br J Anaesth 2014; 112:410.</a></li><li><a class="nounderline abstract_t">Leslie K, Myles PS, Kasza J, et al. Nitrous Oxide and Serious Long-term Morbidity and Mortality in the Evaluation of Nitrous Oxide in the Gas Mixture for Anaesthesia (ENIGMA)-II Trial. Anesthesiology 2015; 123:1267.</a></li><li><a class="nounderline abstract_t">Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology 2008; 109:707.</a></li><li><a class="nounderline abstract_t">Myles PS, Chan MT, Kaye DM, et al. Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function. Anesthesiology 2008; 109:657.</a></li><li><a class="nounderline abstract_t">de Vasconcellos K, Sneyd JR. Nitrous oxide: are we still in equipoise? A qualitative review of current controversies. Br J Anaesth 2013; 111:877.</a></li><li><a class="nounderline abstract_t">Shuhaiber S, Koren G. Occupational exposure to inhaled anesthetic. Is it a concern for pregnant women? Can Fam Physician 2000; 46:2391.</a></li><li><a class="nounderline abstract_t">Buhre W, Disma N, Hendrickx J, et al. European Society of Anaesthesiology Task Force on Nitrous Oxide: a narrative review of its role in clinical practice. Br J Anaesth 2019; 122:587.</a></li></ol></div><div id="topicVersionRevision">Topic 114826 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5844267" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Minimum alveolar anesthetic concentration: a standard of anesthetic potency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203550" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inhalation anesthetics: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633028" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414556" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Minimum alveolar concentration: ongoing relevance and clinical utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30044291" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Minimum Alveolar Concentration-Awake of Sevoflurane Is Decreased in Patients With End-Stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303868" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Best Practices for Postoperative Brain Health: Recommendations From the Fifth International Perioperative Neurotoxicity Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23965188" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The effect of sevoflurane versus desflurane on the incidence of upper respiratory morbidity in patients undergoing general anesthesia with a Laryngeal Mask Airway: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21665899" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Respiratory resistance during anaesthesia with isoflurane, sevoflurane, and desflurane: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9197298" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859465" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pulmonary mechanics during isoflurane, sevoflurane and desflurane anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321464" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Desflurane but not sevoflurane can increase lung resistance via tachykinin pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910489" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Absence of bronchodilation during desflurane anesthesia: a comparison to sevoflurane and thiopental.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20780832" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : THE STAGES AND SIGNS OF GENERAL ANAESTHESIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20780832" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : THE STAGES AND SIGNS OF GENERAL ANAESTHESIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25142708" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15190136" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545294" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26904965" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe Nausea and Vomiting in the Evaluation of Nitrous Oxide in the Gas Mixture for Anesthesia II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151955" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151955" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12751554" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Occupational hazards of inhalational anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12751554" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Occupational hazards of inhalational anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135351" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapid inhalation induction in children: 8% sevoflurane compared with 5% halothane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135350" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhalation induction with sevoflurane: a double-blind comparison with propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12812394" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inhalational techniques in ambulatory anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517657" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multiple-deep-breath inhalation induction with 5% sevoflurane and 67% nitrous oxide: comparison with intravenous injection of propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608808" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620861" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cerebral autoregulation and anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389864" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sevoflurane for difficult tracheal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389864" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sevoflurane for difficult tracheal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704586" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inhalation induction using sevoflurane in children: the single-breath vital capacity technique compared to the tidal volume technique*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27356171" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High initial concentration versus low initial concentration sevoflurane for inhalational induction of anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19108597" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nitrous oxide and the inhalation anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20037150" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188283" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Desflurane: a clinical update of a third-generation inhaled anaesthetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820242" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Statistical modeling of average and variability of time to extubation for meta-analysis comparing desflurane to sevoflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8017643" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rapid increase in desflurane concentration is associated with greater transient cardiovascular stimulation than with rapid increase in isoflurane concentration in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7605020" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dynamic and static cerebral autoregulation during isoflurane, desflurane, and propofol anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984375" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cerebral blood flow autoregulation is preserved during cardiopulmonary bypass in isoflurane-anesthetized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15715133" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Halothane induced hepatitis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12362579" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immune-mediated drug-induced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509326" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adverse drug reactions with halogenated anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25593732" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hepatotoxicity of halogenated inhalational anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/48053" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Controlled prospective study of the effect on liver function of multiple exposures to halothane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22087107" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554286" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Inhaled anesthetic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124411" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A mouse model of severe halothane hepatitis based on human risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of halothane anesthesia on patients with abnormal liver function tests</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749902" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatotoxicity of anesthetics and other central nervous system drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immunopathogenesis and treatment of halothane hepatitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6465580" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Halothane and children: the first quarter century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109584" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Halothane hepatitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2334622" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Halothane metabolism in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29150782" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21965050" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nitrous oxide (N(2)O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21889262" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chronic postsurgical pain after nitrous oxide anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408738" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Does anaesthesia with nitrous oxide affect mortality or cardiovascular morbidity? A systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26501387" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nitrous Oxide and Serious Long-term Morbidity and Mortality in the Evaluation of Nitrous Oxide in the Gas Mixture for Anaesthesia (ENIGMA)-II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18813051" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Biologic effects of nitrous oxide: a mechanistic and toxicologic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18813045" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801743" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nitrous oxide: are we still in equipoise? A qualitative review of current controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153403" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Occupational exposure to inhaled anesthetic. Is it a concern for pregnant women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30916011" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : European Society of Anaesthesiology Task Force on Nitrous Oxide: a narrative review of its role in clinical practice.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
